May 15, 2005|By NEW YORK TIMES NEWS SERVICE
ORLANDO, Fla. - A drug now used to treat breast cancer might be able to prevent prostate cancer in men with a pre-cancerous condition, doctors said here on yesterday. Another study suggested that the widely used cholesterol-lowering drugs called statins might stave off breast cancer.
But experts cautioned that more studies were needed before the drugs were prescribed to prevent prostate and breast cancer.
"We are not ready to recommend statins for those patients who do not have lipid abnormalities," said Dr. Vikas Khurana of Louisiana State University, an author of the statin study, referring to people with high cholesterol.
The findings were discussed here at the annual meeting of the American Society of Clinical Oncology, a group of cancer specialists. The group, which is dedicated mainly to treating cancer, has recently acknowledged that preventing cancer could be every bit as important.
The statin study analyzed the medical records of 40,000 women in the database of the Veterans Affairs medical system. It found that women who used statins were only half as likely to develop breast cancer as those who did not. But such studies looking back at medical records are not as reliable as clinical trials.
The prostate cancer study was a randomized clinical trial involving 514 men with precancerous lesions analogous to polyps for colon cancer. The condition is called Prostate Intraepithelial Neoplasia, or PIN.
No effective treatment exists for the problem, which can be diagnosed only by a pathologist who examines prostate tissue removed in a biopsy. The condition does not always lead to prostate cancer, but men who have it are advised to undergo periodic blood tests and biopsies.
In the study, 24.4 percent of those men who got a once-a-day tablet of toremifene developed prostate cancer after one year, less than the 31.2 percent of those who got a placebo.
Toremifene is a breast cancer drug that is somewhat similar to tamoxifen, in that it blocks the action of the hormone estrogen.
Prostate cancer growth is fueled by the hormone testosterone, and many treatments for the disease block that hormone. But those treatments, effectively chemical castration, cause loss of libido and other side effects.
There is evidence that estrogen, normally thought of as the female hormone, also helps fuel prostate cancer growth. Dr. Mitchell S. Steiner, professor of urology at the University of Tennessee, theorized that blocking estrogen might provide a treatment or preventative with fewer side effects.
So Steiner started a company, GTx, with financial backing from one of his patients, J.R. Hyde III, the founder of AutoZone car parts stores. The company, based in Memphis, has the rights to toremifene and financed the clinical trial.
Dr. Peter Scardino, chief of urology at Memorial Sloan-Kettering Cancer Center in Manhattan, said that the study was well designed and the findings surprising, but that confirmatory studies were needed.
"We are approaching a time when chemo-prevention with hormonal manipulations that are not equivalent of full castration will be feasible," Scardino said in an interview.
One mystery that needs explaining, he said, is that in the trial the lowest dose of drug worked best. Two higher doses did not produce a statistically meaningful reduction in cancer risk.
In the trial, side effects seemed small, doctors said. To win approval of the drug, the company has begun a larger study in which 1,500 men will be followed for at least two years.
The breast cancer study involved female veterans at 10 VA centers in four states. The study compared statin use among 556 women with a history of breast cancer and among 39,865 who did not have the disease.
After statistically controlling for a number of factors like age, smoking and diabetes, the researchers found a 51 percent lower risk of breast cancer among the statin users, Khurana said. He said data on the specific statins that were prescribed have not been analyzed yet.
There have been several studies suggesting that statins might prevent cancer. The studies are "all over the board," said Dr. Barnett S. Kramer of the Office of Disease Prevention at the National Institutes of Health.
